Barclays lowered the firm’s price target on Bath & Body Works to $18 from $28 and keeps an Equal Weight rating on the shares. The company’s Q3 earnings and sales missed expectations and promotions were elevated, the analyst tells investors in a research note. The firm says Bath & Body’s negative trends continued into Q4.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBWI:
- Challenges Ahead: Bath & Body Works Faces Structural Headwinds and Downgrade
- Bath & Body Works downgraded to Equal Weight from Overweight at Morgan Stanley
- Bath & Body Works Unveils Strategic Growth Plan
- Bath & Body Works, Inc. Earnings Call: Strategic Moves Amid Challenges
- Bath & Body Works downgraded to Neutral from Buy at Goldman Sachs